Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
STAR-0215 Granted Fast Track Designation by the U.S. FDA New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 BOSTON (BUSINESS WIRE) Astria Therapeutics, Inc. (NASDAQ:A.
Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks BOST.
Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 Mechanistic. | May 11, 2023
FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 Company to Host a Virtual R&D Day on September 30 BOSTON (BUSINESS WIRE) Astria Therapeutics, Inc..